JP2022536370A5 - - Google Patents

Info

Publication number
JP2022536370A5
JP2022536370A5 JP2021573797A JP2021573797A JP2022536370A5 JP 2022536370 A5 JP2022536370 A5 JP 2022536370A5 JP 2021573797 A JP2021573797 A JP 2021573797A JP 2021573797 A JP2021573797 A JP 2021573797A JP 2022536370 A5 JP2022536370 A5 JP 2022536370A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536370A (ja
JP7680967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037781 external-priority patent/WO2020252471A1/en
Publication of JP2022536370A publication Critical patent/JP2022536370A/ja
Publication of JP2022536370A5 publication Critical patent/JP2022536370A5/ja
Priority to JP2025078346A priority Critical patent/JP2025121996A/ja
Application granted granted Critical
Publication of JP7680967B2 publication Critical patent/JP7680967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573797A 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法 Active JP7680967B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078346A JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861643P 2019-06-14 2019-06-14
US62/861,643 2019-06-14
PCT/US2020/037781 WO2020252471A1 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078346A Division JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022536370A JP2022536370A (ja) 2022-08-15
JP2022536370A5 true JP2022536370A5 (cg-RX-API-DMAC7.html) 2023-06-21
JP7680967B2 JP7680967B2 (ja) 2025-05-21

Family

ID=73781315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573797A Active JP7680967B2 (ja) 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220275088A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982997A4 (cg-RX-API-DMAC7.html)
JP (2) JP7680967B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020290971B2 (cg-RX-API-DMAC7.html)
CA (1) CA3141628A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020252471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2010041060A1 (en) * 2008-10-08 2010-04-15 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
AR088513A1 (es) * 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JP6974311B2 (ja) * 2015-06-23 2021-12-01 メモリアル スローン ケタリング キャンサー センター 新規pd−1免疫調節剤
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
JP6869987B2 (ja) * 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
US10759848B2 (en) * 2016-08-12 2020-09-01 Arsanis Biosciences Gmbh Klebsiella pneumoniae O3 specific antibodies
TWI780083B (zh) * 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
EP3609915A1 (en) * 2017-04-12 2020-02-19 Pfizer Inc Antibodies having conditional affinity and methods of use thereof
CN109575139A (zh) * 2017-09-29 2019-04-05 上海药明生物技术有限公司 针对表皮生长因子受体和程序性死亡受体的双特异抗体
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法

Similar Documents

Publication Publication Date Title
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2022541435A5 (cg-RX-API-DMAC7.html)
JP2022512684A5 (cg-RX-API-DMAC7.html)
JP2019513370A5 (cg-RX-API-DMAC7.html)
JP2018532766A5 (cg-RX-API-DMAC7.html)
JP2019524693A5 (cg-RX-API-DMAC7.html)
IL302278A (en) Combination treatment
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2021522162A5 (cg-RX-API-DMAC7.html)
JP2018532383A5 (cg-RX-API-DMAC7.html)
JP2019519492A5 (cg-RX-API-DMAC7.html)
IL271325B2 (en) Guidance and navigation control proteins and method of making and using thereof
JP2018522888A5 (cg-RX-API-DMAC7.html)
IL295996A (en) Miniature guidance and navigation control (minignc) of antibody-like proteins and methods of production and use thereof
TW202144426A (zh) 四價雙特異性抗體、其製備方法和用途
JP2024541476A5 (cg-RX-API-DMAC7.html)
JP2023524102A5 (cg-RX-API-DMAC7.html)
JP2022536913A5 (cg-RX-API-DMAC7.html)
JP2023544294A5 (cg-RX-API-DMAC7.html)
JP2022513729A5 (cg-RX-API-DMAC7.html)
JP2024539630A5 (cg-RX-API-DMAC7.html)
JP2024546923A5 (cg-RX-API-DMAC7.html)
JP2023116543A5 (cg-RX-API-DMAC7.html)
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof